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The human immunodeficiency virus (HIV) remains a leading cause of maternal morbidity and mortality 
in Sub‑Saharan Africa. Prevention of mother‑to‑child transmission (PMTCT) has proven an effective 
strategy to end paediatric infections and ensure HIV‑infected mothers access treatment. Based on 
cross‑sectional data collected from June 2008 to May 2013, we assessed changes in HIV prevalence, 
risk factors for HIV, provision of PMTCT antiretroviral treatment (ART), and the association between 
HIV infection, birth outcomes and maternal characteristics at the Simão Mendes National Hospital, 
Guinea‑Bissau’s largest maternity ward. Among 24,107 women, the HIV prevalence was 3.3% for HIV‑
1, 0.8% for HIV‑2 and 0.9% for HIV‑1/2. A significant decline in HIV‑1, HIV‑2, and HIV‑1/2 prevalence 
was observed over time. HIV infection was associated with age and ethnicity. A total of 85% of HIV‑
infected women received ART as part of PMTCT, yet overall treatment coverage during labour and 
delivery declined significantly for both mothers and infants. Twenty‑two percent of infants did not 
receive treatment, and 67% of HIV‑2‑infected mothers and 77% of their infants received ineffective 
non‑nucleoside reverse transcriptase inhibitors for PMTCT. Maternal HIV was associated with low 
birth weight but not stillbirth. Inadequate continuity of care and ART coverage present challenges to 
optimal PMTCT in Guinea‑Bissau.
Despite remarkable progress over the past decade, Sub-Saharan Africa (SSA) continues to have the highest global 
prevalence of HIV. Women remain disproportionately at risk of acquiring HIV, with an estimated 59% of all new 
infections occurring amongst  females1. Furthermore, HIV remains one of the leading causes of mortality among 
women of reproductive age in the  region2. In 2017, an estimated 1.3 million pregnant women were living with 
HIV, and 130,000 infants were infected with HIV in  SSA3.
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Approximately 90% of all new paediatric infections occur during the perinatal period, of which 50% occur 
in relation to labour and  delivery4,5. Antiretroviral treatment (ART) as part of prevention of mother-to-child 
transmission (PMTCT) is a key strategy to combat the African HIV epidemic and decreases vertical transmission 
rates from as high as 45% to < 5% in breastfeeding  populations6. PMTCT has yielded remarkable results, with 
an estimated 93% of pregnant women in eastern and southern Africa living with HIV receiving antiretroviral 
prophylaxis, resulting in mother-to-child transmission rates of less than 10%. Nevertheless, western and central 
Africa appear to lag behind, with fewer than half (48%) of pregnant women living with HIV in 2017 receiving 
PMTCT  services1.
Guinea-Bissau is a West African country populated with 1.8 million inhabitants, of which 400,000 reside in 
the capital Bissau. According to the joint United Nations programme on HIV/AIDS (UNAIDS), 3.4% (95% CI 
2.6–3.8) of the population in Guinea-Bissau is infected with HIV (UNAIDS, 2018c), yet the true number may 
be notably higher considering that HIV prevalence in the country’s capital is 6.7%7. A previous study among 
pregnant women conducted from 2002 to 2006 found that 5.7% were HIV-1 infected, and 2.4% were HIV-2 
infected, including 0.7% HIV-1/2 dually infected  women8.
The Ministry of Health in Guinea-Bissau implemented a national HIV program in 2005, providing free of 
charge ART. Yet, more than a decade later, the country remains far from achieving the 90–90–90  targets1. The 
delivery of HIV treatment has been impeded by numerous barriers including political instability, frequent HIV 
clinic relocations and inadequate drug supply resulting in treatment  interruptions9. In addition, poor laboratory 
capacity, inadequate validation of HIV rapid tests, repeated unavailability of CD4 cell count measurements, and 
lack of access to HIV-RNA measurement have delayed initiation of ART and led to the identification of treat-
ment  failure9,10. As a result, UNAIDS estimated that only 32% of adults in the country accessed antiretroviral 
therapy in  201811.
PMTCT counselling and testing has been available at selected antenatal clinics (ANC) in Bissau since  20028. 
Between October 2007 and April 2013, 86% of pregnant women had at least one antenatal visit, but only 54% 
attended all four recommended visits in Bissau. In addition, only 29% of women in rural areas and 69% of women 
in urban settings delivered at health facilities in the  country12. Previous qualitative research from Guinea-Bissau 
has shown that a lack of HIV and PMTCT knowledge, customary and cultural beliefs associated with HIV and 
ill health, HIV stigma and discrimination, and fear of partnership dissolution were common barriers to PMTCT 
13. In addition, a study exploring peripartum opt-out testing found that regular stock interruptions and political 
instability negatively affected the provision of PMTCT 14. High rates of early mortality and loss to follow-up have 
recently been described among HIV-infected children (< 15 years of age) in Guinea-Bissau. Based on a study 
of 525 HIV-infected children, 11% died and 39% were lost to follow-up within the first year of follow-up, high-
lighting continuous challenges with implementing sustainable PMTCT  services15. Consequently, there remains 
a paucity of research exploring the delivery of PMTCT services with the overall aim of improving treatment and 
care for HIV-infected mothers and their children in Guinea Bissau.
In this retrospective study, we assessed changes in HIV-1 and HIV-2 prevalence, factors associated with 
HIV infection, birth outcomes and the provision of ART as part of PMTCT services over a 5-year period at the 
national maternity ward in Bissau, Guinea-Bissau.
Methods
Study setting. The study was conducted by the Bandim Health Project (BHP) (https ://www.bandi m.org) at 
the Simão Mendes National Hospital (HNSM) maternity ward located in Bissau. The BHP, a health and demo-
graphic surveillance site present in Guinea-Bissau for 4 decades, routinely collects demographic and clinical 
data on all deliveries at HSNM. This public facility is the principal provider of comprehensive obstetric care in 
Guinea-Bissau, and approximately 90% of women who deliver at the facility are residents of the country’s capital, 
Bissau.
From June 2008 onwards, opt-out HIV counselling and testing has been offered to women admitted to the 
maternity ward for the management of labour- and delivery- and/or pregnancy-related complications when HIV 
tests were available. HIV testing and ART were free of charge and provided by the Guinean Ministry of Health, 
but all women paid a flat fee of 2000 XOF (3–4 USD) to give birth at  HNSM14. All newly diagnosed women 
and their infants were referred to the Italian-Guinean NGO-clinic, Ceu e Terras, or to other local HIV centres 
for follow-up, counselling, and further PMTCT ART 13. Data registration of testing for HIV at delivery ceased 
in May 2013 due to funding constraints. While HIV testing at labour and delivery was national policy at the 
time of the study, not all women were tested. We have previously described the characteristics of women tested 
compared with those not tested 14.
Study design and participants. We conducted a retrospective cross-sectional survey exploring HIV 
prevalence, risk factors for HIV, treatment provision, and birth outcomes (low birth weight, LBW, and stillbirth), 
drawing on data routinely collected through the BHP surveillance system at HNSM from June 2008 until May 
2013. All women presenting to HNSM for delivery or immediate postpartum care who had been tested for HIV 
were included in this study.
Data collection. Data were recorded in the HNSM maternity ward registration system and included basic 
socio-demographic and clinical data. Data cleaning was performed daily (including weekends) by trained 
research assistants from BHP who also collected supplementary demographic and clinical information using 
separate case report forms (CRFs). We have previously described the data collected in  detail14,16. During the 
study period, it was national policy that hospital midwives offer immediate HIV counselling and testing to all 
women presenting to the maternity for delivery or, as many women had not attended ANC or did not receive 
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PMTCT testing or counselling during pregnancy. Midwives had been trained to complete a short CRF as part of 
the counselling and testing routine to collect data on previous HIV testing, known sero-status, and ART  use14.
HIV testing. HIV screening was performed using the Determine® HIV-1/2 rapid test (Abbot Diagnostics, 
Maidenhead, United Kingdom). To confirm infection and to discriminate between HIV types, women with posi-
tive and inconclusive screening results were subsequently tested with another rapid test, SD Bioline HIV-1/2 3.0 
(Standard Diagnostics, Kyonggi-do, South Korea).
HIV treatment regimens. Provision of PMTCT at the initiation of this survey was guided by the 2006 
World Health Organization (WHO) recommendations, i.e., ART prophylaxis in the third trimester (28 weeks) 
of pregnancy consisting of a regimen of twice daily Zidovudine (AZT), single-dose nevirapine (sd NVP) at 
onset of labour and Zidovudine plus Lamivudine (AZT + 3TC) for 1 week from birth. Women diagnosed in 
labour were given a single-dose nevirapine followed by AZT + 3TC for 1 week starting in labour. For women 
who needed treatment for their own health, triple ART (cART) was initiated as soon as possible. For HIV-2 and 
HIV-1/2 dually infected mothers, a combination of (AZT + 3TC) + Lopinavir/Ritonavir was recommended. For 
infants, guidelines recommended sd NVP plus AZT twice a day for either 4 weeks if the mother had received 
less than 4 weeks AZT prophylaxis prior to labour or for 1 week if the mother had received at least 4 weeks 
AZT prophylaxis. Infants of mothers receiving cART were recommended AZT twice  daily17. After 2010, in line 
with the revised WHO recommendations, all pregnant women with CD4 count levels < 350 cells/mm3, irre-
spective of clinical stage, and women with a WHO clinical stage 3 or 4 infection, were started on triple ART. 
In addition, women not receiving ART for their own health, received (Option A) prophylaxis with AZT as 
monotherapy from as early as 14 weeks of pregnancy plus a single dose NVP + AZT + 3TC during labour and 
delivery followed by AZT + 3TC for 7 days after delivery, or triple ART prophylaxis (Option B) from as early as 
14 weeks of pregnancy. The infant regime consisted of daily NVP from birth for a minimum of 4–6 weeks, and 
until 1 week after all exposure to breastmilk had ended. For infants receiving replacement feeding only daily 
NVP or sd NVP + daily AZT from birth and until 4–6 weeks of age was  recommended18. Due to logistical issues, 
treatment was often started without CD4 cell count measurements based on clinical assessment. Throughout the 
study period, repeated stock outages and lack of ART at times forced clinicians to switch treatment and often to 
provide more simple regimes than  recommended9, 19. In 2015, Guinea-Bissau began implementing option B+, 
i.e., lifelong ART from  diagnosis20,21.
Statistical methods. Maternity and HIV testing data were entered in password-secured databases (dBase 
5.0, dataBased Inc, Vestal, NY, USA; Microsoft Access 2007, Microsoft, Redmond, WA, USA), and datasets 
were merged using unique birth numbers. The data were analysed using Stata 14.0 (Stata Corporation, College 
Station, TX, USA). Outcome variables such as LBW and stillbirths were dichotomized (0 = absent, 1 = present). 
Continuous explanatory variables were grouped categorically. Factors associated with HIV serostatus and birth 
outcomes were determined using univariate and multivariate logistical regression models. The multivariate anal-
ysis was fitted with statistically significant covariates (as determined by Wald’s test). Birth outcomes i.e., still-
births and low birthweight (LBW) were examined according to HIV status and adjusted for significant covari-
ates. In accordance with the WHO criteria, stillbirth was defined as a newborn at or above 1,000 g showing no 
vital signs immediately after birth (Apgar score = 0)22. Low birth weight was defined as birth weight of < 2,500 g23. 
Miscarriages (birth weight < 1,000 g) were excluded. In the birth outcome analysis, “births” pertain to the num-
ber of fetuses at risk. Therefore, the number of total births is higher than the number of pregnant women due 
to multiple pregnancies. In the logistic regression models, adjustment for birth outcomes was made for cluster-
ing of twins using a specific pair number. Inconclusive test results were categorized as HIV-negative. Missing 
values were included in the logistic regression models. Trends over time (calendar year) for HIV prevalence and 
treatment were determined using Pearson’s χ2 test. Due to a lack of data to confirm self-reported antenatal treat-
ment regimens and reasons for selecting a given treatment at labour, we opted to assess antenatal and treatment 
at labour separately. A p value of < 0.05 was considered significant.
Ethical considerations. All patient data were fully anonymised before being accessed. The use of govern-
ment surveillance maternity data was approved by the National Ethical Committee in Guinea-Bissau (CNES-
2010-018). A separate ethical approval was obtained for the analysis of HIV data and linkage of delivery and HIV 
databases (CNES-2011-030). The study was carried out in accordance with Guinea-Bissau Medical Research 
Ethics Committee requirements and the Helsinki declaration. All participants were counselled and asked for 
verbal informed consent before data collection and HIV testing. Newly diagnosed women were offered ART at 
labour and subsequently referred for follow-up. The manuscript was prepared in accordance with the STROBE 
guidelines (Supplemental Checklist 1).
Results
Participant characteristics. From June 2008 to May 2013, a total of 31,443 women presented to the 
HNSM maternity ward for delivery and/or pregnancy-related care, of which 77% (n = 24,107) were tested for 
HIV (Fig.  1). The median age of women was 24  years (inter-quartile range [IQR] 20–29, range 13–49). The 
principal ethnic groups were the Balanta (23%) and the Fula (22%). Forty-five percent of women had no or little 
(primary) education, and 19% reported a polygamous marriage (Table 1). 
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Prevalence of HIV. A total of 5.1% (1,232/24,107) of women were infected with HIV. The overall prevalence 
of HIV-1 was 3.3% (95% CI 3.1–3.5), the HIV-2 prevalence was 0.8% (95% CI 0.7–0.9), and HIV-1/2 dually 
infected women accounted for 0.9% (95% CI 0.8–1.1). Nineteen women who tested positive did not have the 
HIV type discriminatory test performed (Fig. 1).
Among women tested at birth, 47% (11,233/24,107) reported prior HIV testing during antenatal visits. Among 
them, 5.0% (566/11,233) were HIV positive, 93% (10,444/11,233) were HIV negative, 0.1% (9/11,233) were inde-
terminate and 1.9% (214/11,233) could not remember. Comparing self-reported and observed HIV test results, 
we found that 3.4% (19/566) of women with self-reported HIV-positive status tested HIV negative in labour, 
and 1.9% (197/10,444) of self-reported HIV negative women were HIV positive at delivery. Of the women who 
could not remember their HIV status, 15% (32/214) were HIV positive.
Variations in HIV‑1 and HIV‑2 prevalence. There was a significant decline in HIV-1 prevalence from 
4.0% (95% CI 3.5–4.6) in 2009 to 2.5% (95% CI 1.8–3.3) in 2013, p < 0.024. HIV-2 prevalence declined from 
1.2% (95% CI 0.9–1.5) in 2009 to 0.5% (95% CI 0.2–0.8) in 2013, p < 0.017 (Fig. 2). Exploring changes in HIV 
prevalence by age groups, we observed that the decline in HIV-1 and HIV-1/2 prevalence was largely confined 
to older women (aged ≥ 25 years), while the decline in HIV-2 prevalence was independent of age (Supplemental 
Figure 1).
Risk determinants of HIV‑1 and HIV‑2 infection. Based on univariate analysis, we found maternal age, 
marital status, parity, and calendar year were associated with HIV-1, HIV-2 and HIV-1/2. Surprisingly, educa-
tion was not significantly associated with HIV status and was therefore excluded from the multivariate analysis. 
As expected, the risk of HIV-1 increased significantly with age in the multivariate model (Table 2). Women 
belonging to the Balanta [adjusted odds ratio [AOR] 1.41 (95% CI 1.09–1.82)], Fula [1.33 (95% CI 1.02–1.73)] 
and Mandinga [1.37 (95% CI 1.01–1.86)] ethnic groups, and women from smaller ethnic groups or non-Guin-
ean heritage [2.08 (95% CI 1.60–2.70)], had a higher HIV-1 prevalence compared with the Pepel ethnic group. 
For HIV-2, only age was significantly associated with HIV infection. Lastly, we found age, the Mandinga ethnic-
ity and calendar year were associated with HIV-1/2 (Table 2). 
Women presenting to HNSM  
(June 2008 to May 2013) 
N=31,443 
HIV-1 
n= 795 (65.5%) 
HIV-1/2 (D) 
n=222(18.3%) 
HIV-2 
n=196(16.2%) 
HIV type unknown 
n=19(1.5%) 
HIV positive 
n=1,232 (5.1%) 
Negative 
n=22,866 (94.9%) 
Indeterminate 
n=9 (0.0%) 
Not tested 
n=7,336 (23.3%) 
Tested 
n= 24,107 (76.7%) 
Included 
Excluded 
HIV type known 
n=1,213 (99%) 
Figure 1.  Flow diagram of participants included in the study. The flow diagram displays women included in 
this study according to HIV status.
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ART and PMTCT regimens. Of women diagnosed antenatally (N = 566), 70% (396/566) reported receiv-
ing AZT prophylaxis, while 11% (62/566) reported receiving cART. Nineteen percent (108/566) reported that 
they were not receiving treatment or could not remember. Among women diagnosed in labour and women 
reporting no antenatal ART, 19% (149/774) received cART, 14% (108/774) received AZT prophylaxis plus a 
sd NVP + initiation of 3TC + AZT at childbirth, while 52% (408/774) of women, first diagnosed at delivery, 
received only sd NVP. Fourteen percent (109/774) did not receive any treatment at delivery. For women with 
HIV-2 (n = 196), 39% (76/196) received prophylaxis AZT plus a single dose-NVP + initiation of 3TC + AZT at 
childbirth, while 28% (55/196) received sd NVP only. Among women aware of their HIV status prior to labour 
and delivery, we observed a significant increase in self-reported antenatal treatment coverage from 60% in 2008 
to 85% in 2013, p < 0.001. Specifically, there was an increase in women receiving antenatal AZT prophylaxis 
from 55% in 2008 to 82% in 2013, while there was no overall increase in cART during the same period (Fig. 3a). 
For women diagnosed at delivery and HIV-positive women not receiving antenatal ART (excluding women 
Table 1.  Baseline characteristics of pregnant women tested for HIV stratified by HIV-1, HIV-2 and HIV-
1/2 status from June 2008 to May 2013 (N = 24,107). p-values < 0.05 highlighted in bold. NA, Not available; 
p, p-value. a Ethnic groups or nationalities, each comprising less than 1% of the sample population i.e., Cape 
Verdean, Senegalese, Guinean (Republic of Guinea), Balanta Mane, Mansoanca, Nalu, and Geba. b Including 
widowed, divorced or separated. c Including index pregnancy.
Baseline characteristics
Study population HIV-1 positive HIV-2 positive HIV-1/2 positive
N = 24,107 (col%) n = 795 (row%) p n = 196 (row%) p n = 222 (row%) p
Age < 0.001 < 0.001 < 0.001
Age 13–19 5,655 (23.5) 68 (1.2) 11 (0.2) 11 (0.2)
Age 20–24 7,215 (29.9) 234 (3.2) 38 (0.5) 55 (0.8)
Age 25–29 6,238 (25.9) 270 (4.3) 63 (1.0) 80 (1.3)
Age 30+ 4,999 (20.7) 223 (4.5) 84 (1.7) 76 (1.5)
Ethnic group < 0.001 0.749 0.016
Balanta 5,476 (22.7) 189 (3.5) 42 (0.8) 37 (0.7)
Bijagos 436 (1.8) 9 (2.1) 3 (0.7) 4 (0.9)
Felupe 374 (1.6) 7 (1.9) 3 (0.8) 1 (0.3)
Fula 5,262 (21.8) 159 (3.0) 37 (0.7) 46 (0.9)
Mancanha 1,878 (7.8) 62 (3.3) 15 (0.8) 20 (1.1)
Mandinga 2,485 (10.3) 85 (3.4) 27 (1.1) 39 (1.6)
Manjaco 1,860 (7.7) 55 (3.0) 17 (0.9) 19 (1.0)
Mixed ethnicity 682 (2.8) 23 (3.4) 9 (1.3) 9 (1.3)
Pepel 3,495 (14.5) 91 (2.6) 29 (0.8) 26 (0.7)
Saracule 252 (1.1) 6 (2.4) 3 (1.2) –
Othera 1,886 (7.8) 107 (5.7) 11 (0.6) 21 (1.1)
NA 21 (0.1) 2 (9.5) 0 (0.0) –
Marital status < 0.001 0.001 0.036
Single 6,591 (27.3) 174 (2.6) 33 (0.5) 42 (0.6)
Married-monogamous 12,571 (52.2) 430 (3.4) 106 (0.8) 129 (1.0)
Married-polygamous 4,584 (19.0) 186 (4.1) 54 (1.2) 46 (1.0)
Otherb 361 (1.5) 5 (1.4) 3 (0.8) 5 (1.4)
Education 0.056 0.245 0.850
None/primary education (0–6) 10,746 (44.6) 370 (3.4) 88 (0.8) 102 (1.0)
Secondary education (7–12+) 11,293 (46.8) 375 (3.3) 85 (0.8) 103 (0.9)
NA 2,068 (8.6) 50 (2.4) 23 (1.1) 17 (0.8)
Parityc < 0.001 < 0.001 < 0.001
1 8,966 (37.2) 191 (2.1) 31 (0.4) 42 (0.5)
2 5,534 (23.0) 205 (3.7) 48 (0.9) 55 (1.0)
≥ 3 9,136 (37.9) 391 (4.3) 113 (1.2) 117 (1.3)
Unknown 471 (2.0) 8 (1.7) 4 (0.9) 8 (1.7)
Year of delivery 0.024 0.017 < 0.001
2008 (June–December) 1,514 (6.3) 46 (3.0) 9 (0.6) 23 (1.5)
2009 4,801 (19.9) 191 (4.0) 56 (1.2) 74 (1.5)
2010 6,534 (27.1) 220 (3.4) 52 (0.8) 58 (0.9)
2011 3,901 (16.2) 126 (3.2) 24 (0.6) 27 (0.7)
2012 5,336 (22.1) 162 (3.0) 46 (0.9) 29 (0.5)
2013 (January–May) 2,021 (8.4) 50 (2.5) 9 (0.5) 11 (0.5)
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already on treatment, n = 458), overall treatment coverage declined from 99% in 2008 to 50% in 2013, p < 0.001. 
Notably, the proportion of women not receiving treatment at birth  increased steadily throughout the study 
period (Fig. 3b). Figure 3 shows the provision of self-reported antenatal treatment and treatment at birth among 
HIV-infected women at the HNSM. During the study period, 85% of all HIV-infected women (1,049/1,232) 
received some form of ART in relation to labour for PMTCT. The majority (34%, n = 418) received option A, 33% 
(n = 408) received sd NVP, 18% (n = 223) received triple ART and 15% (n = 183) did not receive any treatment. 
As with women diagnosed at delivery, we observed a steady increase in the number of women not receiving any 
treatment despite including women diagnosed antenatally (Fig. 4). 
Among infants of HIV-infected mothers (including twins and triplets), 8% (103/1,275) received the recom-
mended treatment of sd NVP followed by AZT treatment, 70% (891/1,275) received sd NVP, and 22% (281/1,275) 
did not receive any treatment. Among infants of HIV-2 infected mothers, 77% (156/202) received sd NVP or sd 
NVP followed by AZT. The number of infants not receiving treatment to prevent mother-to-child transmission 
increased from 7% in 2008 to 36% in 2013, p < 0.001 (Supplemental Figure 2).
Birth outcomes. Seventeen percent (4,213/25,232) of births were LBW, and 10% (2,513/25,256) of 
babies were stillborn. Factors independently associated with LBW and stillbirths are displayed in Supplemental 
Table 1. We found no association between antenatal treatment and birth outcomes. Assessing birth outcomes 
for HIV-1, HIV-2 and HIV-1/2 dually infected women compared with HIV negative women, we found that 
maternal HIV-1 and HIV-1/2 co-infection were associated with LBW, AOR 1.25 (95% CI 1.03–1.52) and AOR 
1.73 (95% CI 1.26–2.37), respectively (Table 3). No significant association was found between HIV status and 
stillbirth in univariate or multivariate analyses (Table 4). 
Discussion
This retrospective cross-sectional study examined HIV-1 and HIV-2 prevalence and factors associated with HIV, 
PMTCT treatment coverage and adverse birth outcomes at the largest maternity ward in Guinea-Bissau. It shows 
a decline in HIV-1, HIV-2, HIV-1/2 prevalence among pregnant women presenting for labour during a 5-year 
Figure 2.  Prevalence of HIV-1 and HIV-2 in pregnant women by calendar year, Simão Mendes National 
Hospital, Bissau, Guinea-Bissau, 2008–2013. The figure displays the changes in HIV-1 (a), HIV-2 (b), and 
HIV-1/2 (c) prevalence (point estimates and corresponding 95% confidence intervals) among pregnant women 
presenting for birth by calendar year. HIV-1, HIV-2 and HIV-1/2 all declined significantly from 2009 to 2013 
 (chi2 test for trend).
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HIV-1 positive n = 795 HIV-2 positive n = 196 HIV-1/2 positive n = 222
Coefficient ± SE
AOR (95% 
CI)a p Coefficient ± SE
AOR (95% 
CI)a p Coefficient ± SE
AOR (95% 
CI)a p
Age groups
Age 13–19 1.00 1.00 1.00
Age 20–24 0.94 ± 0.15 2.55 (1.91–3.40) < 0.001 0.82 ± 0.36
2.27 (1.12–
4.59) 0.022 1.29 ± 0.34
3.65 (1.86–
7.14) < 0.001
Age 25–29 1.21 ± 0.16 3.35 (2.47–4.54) < 0.001 1.41 ± 0.36
4.10 (2.01–
8.36) < 0.001 1.80 ± 0.35
6.04 (3.04–
12.01) < 0.001
Age 30+ 1.25 ± 0.17 3.50 (2.52–4.85) < 0.001 1.91 ± 0.38
6.77 (3.24–
14.13) < 0.001 1.99 ± 0.37
7.34 (3.58–
15.05) < 0.001
Ethnic group
Balanta 0.34 ± 0.13 1.41 (1.09–1.82) 0.009 0.01 ± 0.24
1.01 
(0.62–1.62) 0.984 − 0.01 ± 0.26
0.99 
(0.60–1.65) 0.977
Bijagos − 0.26 ± 0.35 0.77 (0.39–1.54) 0.463 − 0.22 ± 0.61
0.80 
(0.24–2.65) 0.719 0.20 ± 0.54
1.22 
(0.42–3.51) 0.718
Felupe − 0.35 ± 0.40 0.71 (0.32–1.54) 0.381 0.01 ± 0.61
1.00 
(0.30–3.33) 0.992 − 1.06 ± 1.02
0.35 
(0.05–2.58) 0.302
Fula 0.28 ± 0.14 1.33 (1.02–1.73) 0.038 0.03 ± 0.25
1.03 
(0.63–1.70) 0.905 0.35 ± 0.25
1.42 
(0.87–2.32) 0.167
Mancanha 0.19 ± 0.17 1.21 (0.87–1.68) 0.253 − 0.09 ± 0.32
0.91 
(0.49–1.71) 0.775 0.29 ± 0.30
1.34 
(0.74–2.40) 0.336
Mandinga 0.32 ± 0.16 1.37 (1.01–1.86) 0.041 0.33 ± 0.27
1.39 
(0.82–2.36) 0.227 0.82 ± 0.26
2.28 (1.38–
3.77) 0.001
Manjaco 0.08 ± 0.17 1.08 (0.77–1.52) 0.658 0.02 ± 0.31
1.02 
(0.56–1.87) 0.945 0.22 ± 0.30
1.25 
(0.69–2.27) 0.461
Mixed 
ethnicity 0.17 ± 0.24
1.19 
(0.75–1.90) 0.465 0.34 ± 0.39
1.41 
(0.66–3.01) 0.373 0.46 ± 0.39
1.58 
(0.74–3.41) 0.240
Pepel 1.00 1.00 1.00
Saracule − 0.10 ± 0.43 0.70 (0.30–1.60) 0.818 0.39 ± 0.62
1.48 
(0.45–4.95) 0.521 – – –
Othersb 0.80 ± 0.15 2.08 (1.60–2.70) < 0.001 − 0.35 ± 0.36
0.70 
(0.35–1.41) 0.322 0.40 ± 0.30
1.50 
(0.84–2.68) 0.173
NA 1.29 ± 0.76 2.78 (0.63–12.20) 0.089 – – –
Marital status
Single 1.00 1.00 1.00
Married-
monoga-
mous
− 0.12 ± 0.10 0.89 (0.72–1.08) 0.238 − 0.09 ± 0.22
0.92 
(0.59–1.42) 0.696 − 0.09 ± 0.20
0.92 
(0.62–1.36) 0.668
Married-
polyga-
mous
0.00 ± 0.12 1.00 (0.79–1.27) 0.999 0.11 ± 0.25
1.11 
(0.68–1.83) 0.678 − 0.18 ± 0.20
0.84 
(0.52–1.35) 0.473
Otherc − 0.76 ± 0.68 0.47 (0.12–1.78) 0.2634 − 0.13 ± 1.03
0.88 
(0.12–6.53) 0.897 − 0.80 ± 0.74
0.45 
(0.11–1.91) 0.277
Parity
1d 1.00 1.00 1.00
2 0.22 ± 0.11 1.25 (1.00–1.55) 0.052 0.45 ± 0.25
1.57 
(0.96–2.58) 0.076 0.27 ± 0.22
1.30 
(0.84–2.02) 0.234
≥ 3 0.19 ± 0.12 1.21 (0.96–1.52) 0.113 0.37 ± 0.26
1.44 
(0.86–2.40) 0.161 0.24 ± 0.23
1.27 
(0.81–1.98) 0.300
NA − 0.08 ± 0.55 0.93 (0.32–2.70) 0.890 0.39 ± 0.90
1.48 
(0.25–8.60) 0.665 1.34 ± 0.60
3.80 
(1.17–12-
35)
0.026
Year
2008 
(June–
December)
1.00 1.00 1.00
2009 0.25 ± 0.17 1.29 (0.92–1.79) 0.136 0.63 ± 0.36
1.87 
(0.92–3.80) 0.084 − 0.01 ± 0.24
0.99 
(0.62–1.60) 0.978
2010 0.07 ± 0.17 1.07 (0.77–1.48) 0.693 0.21 ± 0.36
1.24 
(0.61–2.53) 0.561 − 0.57 ± 0.25
0.56 
(0.35–0.92) 0.022
2011 0.01 ± 0.18 1.01 (0.72–1.43) 0.943 − 0.06 ± 0.39
0.94 
(0.43–2.03) 0.872 − 0.84 ± 0.29
0.43 (0.25–
0.76) 0.003
2012 − 0.07 ± 0.17 0.93 (0.67–1.31) 0.687 0.28 ± 0.37
1.32 
(0.64–2.71) 0.450 − 1.11 ± 0.28
0.33 (0.19–
0.57) < 0.001
Continued
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period. Women from the Balanta and Fula ethnic groups had a significantly higher risk of HIV-1. Antenatal treat-
ment coverage appears to be improving over time, yet an increase in the proportion of mothers and infants not 
receiving treatment at birth was observed, inevitably increasing the overall risk of mother-to-child transmission. 
This is specifically alarming as nearly half of the women were unaware of their HIV status prior to presenting for 
labour. Over the 5-year period, 15% of HIV-infected mothers and 22% of infants born to HIV-infected mothers 
did not receive any treatment. In addition, 67% of mothers with HIV-2 received NVP, which is ineffective against 
HIV-2 infection. Lastly, infants born to mothers with HIV-1 or HIV-1/2 dually infected were at risk of being LBW.
The HIV-2 prevalence of 0.8% in this survey was notably lower than in previous surveys among pregnant 
women, suggesting a continuing decline in HIV-2 prevalence in Guinea-Bissau8,24–26. A national survey from 
2013 conducted in all 10 regions of the country reported an HIV-2 (including HIV-1 co-infected) prevalence of 
1.0% (95% CI 0.5–1.8)27. In addition, a recently published study from the Bandim Health Project demographic 
Table 2.  Risk factors for HIV-1, HIV-2, and HIV-1/2 dual infection among all women tested for HIV at 
labour and delivery. p-values < 0.05 highlighted in bold. NA, Not available; SE, Standard error; AOR, adjusted 
odds ratio; CI, confidence intervals; p, p-value. a Variables associated with HIV-1, HIV-2 or HIV-1/2 infection 
in the univariate analysis (p < 0.05) were included in the multivariate model. b Ethnic groups or nationalities, 
each comprising less than 1% of the sample population i.e., Cape Verdean, Senegalese, Guinean (Republic 
of Guinea), Balanta Mane, Mansoanca, Nalu, and Geba. c Separated, divorced or widowed. d Including index 
pregnancy.
HIV-1 positive n = 795 HIV-2 positive n = 196 HIV-1/2 positive n = 222
Coefficient ± SE
AOR (95% 
CI)a p Coefficient ± SE
AOR (95% 
CI)a p Coefficient ± SE
AOR (95% 
CI)a p
2013 (Janu-
ary–May) − 0.28 ± 0.21
0.76 
(0.50–1.14) 0.177 − 0.42 ± 0.48
0.66 
(0.26–1.66) 0.375 − 1.13 ± 0.37
0.33 (0.16–
0.67) 0.002
Constant − 4.71 ± 0.22 – − 6.58 ± 0.49 – − 6.00 ± 0.42 –
Figure 3.  Self-reported antenatal treatment (a) and treatment provided at birth (b) by calendar year, Simão 
Mendes National Hospital, Bissau, Guinea-Bissau, 2008–2013. cART combined antiretroviral therapy, AZT 
Zidovudine, 3TC Lamivudine, sd NVP single-dose Nevirapine. (a) Self-reported treatment regimens received 
by HIV-positive women presenting for labour by calendar year (N = 566). As shown, the percentage of women 
receiving AZT prophylaxis increased between 2008 and 2013, while the percentage of women on cART 
increased slightly from 2008 to 2011 and declined thereafter. (b) The provision of antiretroviral treatment at 
birth by calendar year, excluding women who reported initiating ART during the antenatal period (N = 774). 
The figure shows that the proportion of women receiving combined antiretroviral treatment increased steadily 
between 2009 and 2012, yet the percentage decreased between 2012 and the first quarter of 2013. Conversely, 
a decline in women receiving option A [AZT prophylaxis + (AZT + 3TC and sd NVP at labour)] between 2008 
and 2013 was observed. Women receiving only sd NVP declined notably, suggesting that more women were 
initiated on treatment before labour. During the same period, we observed a notable increase in the number of 
HIV-infected women not receiving treatment at delivery. The p values shown were estimated using the  chi2 test 
for trend.
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surveillance site found an HIV-2 prevalence of 1.5% among younger women (aged 15–44 years)7. Changes in risk 
behaviour over the past decades and competitive exclusion have been proposed as  explanations28,29. Modelling 
predicts that new HIV-2 cases in the country will cease within a few decades 30. In contrast, previous surveys 
Figure 4.  The provision of antiretroviral treatment for all HIV-infected women by calendar year, Simão Mendes 
National Hospital, Bissau, Guinea-Bissau, 2008–2013. cART combined antiretroviral therapy, AZT Zidovudine, 
3TC Lamivudine, sd NVP single-dose Nevirapine. The figure displays the provision of antiretroviral treatment 
at birth by calendar year for all HIV women in this study (N = 1,232). Overall coverage for cART and option A 
(AZT + 3TC + sd NVP) remained relatively low throughout the study period. There was a decline in the number 
of women receiving sd NVP, while the overall number of women not receiving any treatment increased over 
time. The p value shown was estimated using the  chi2 test for trend.
Table 3.  Crude and adjusted odds ratios for low birth weight according to HIV status among mothers 
presenting for labour in Bissau, Guinea-Bissau (N = 25,232). p-values < 0.05 highlighted in bold. BW, birth 
weight; SE, Standard error; COR, crude odds ratio; CI, confidence intervals; AOR, adjusted odds ratio; p, 
p-value. a Including twin and triplet births. b Adjusted for age by groups, ethnicity, marital status, education, 
parity, vital status of last-born child, previous antenatal counselling, Bissau resident (resident or referral patient 
from another region) and twin birth.
Maternal HIV status 
(N = 24,107) Low birth weight (BW < 2,500 g)a (N = 25,232)
n (col%) Yes n (row%) Coefficient ± SE COR (95% CI) p Coefficient ± SE AOR (95% CI)b p
Negative 22,894 (95.0%) 3,991 (17.4%) 1.00 1.00
HIV-1 795 (3.3%) 140 (17.6%) 0.05 ± 0.10 1.05 (0.87–1.26) 0.604 0.22 ± 0.10 1.25 (1.03–1.52) 0.027
HIV-2 196 (0.8 %) 28 (14.3%) − 0.20 ± 0.21 0.82 (0.55–1.22) 0.320 − 0.03 ± 0.22 0.97 (0.64–1.48) 0.882
HIV-1/2 222 (0.9%) 54 (24.3%) 0.42 ± 0.16 1.52 (1.12–2.07) 0.007 0.55 ± 0.16 1.73 (1.26–2.37) 0.001
Constant − 1.61 ± 0.02 − 2.26 ± 0.22
Table 4.  Crude and adjusted odds ratios for stillbirth according to HIV status among mothers presenting 
for labour in Bissau, Guinea-Bissau (N = 25,256). SE, Standard error; COR, crude odds ratio; CI, confidence 
intervals; AOR, adjusted odds ratio; p, p-value. a Including twin and triplet births. b Adjusted for age by groups, 
ethnicity, marital status, education, parity, caesarean-section, vital status of last-born child, previous antenatal 
counselling, Bissau resident (resident or referral patient from another region), low birth weight and twin birth.
Maternal HIV status 
(N = 24,107) Stillbirth (N = 25,256)a
n (col%) Yes n (%) Coefficient ± SE COR (95% CI) p Coefficient ± SE AOR (95% CI)b p
Negative 22,894 (95.0%) 2,382 (10.4%) 1.00 1.00
HIV-1 795 (3.3%) 81 (10.2%) 0.01 ± 0.12 1.01 (0.80–1.28) 0.930 0.05 ± 0.13 1.05 (0.82–1.36) 0.692
HIV-2 196 (0.8%) 22 (11.2%) 0.12 ± 0.23 1.12 (0.72–1.75) 0.611 0.04 ± 0.25 1.00 (0.62–1.63) 0.988
HIV-1/2 222 (0.9%) 28 (12.6%) 0.22 ± 0.20 1.25 (0.84–1.85) 0.277 0.01 ± 0.22 1.01 (0.65–1.56) 0.958
Constant − 2.21 ± 0.02 − 4.40 ± 0.22
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from Guinea-Bissau have shown increasing or stabilized HIV-1 prevalence among a range of  populations7,24,26,31. 
Gianelli et al.8 found that HIV-1 prevalence among pregnant women stabilized between 2003 and 2006. Our 
study is supported by findings from a recent national survey suggesting that the HIV-1 prevalence has stabilized 
and may be declining among women of reproductive  age27. The risk of HIV transmission decreases substan-
tially with ART 32, and the decline in HIV-1 and HIV-2 may in part reflect the fruits of national interventions, 
including efforts to strengthen prevention measures during the roll-out of ART. Nevertheless, inadequate health 
infrastructure, repeated drug stock outages, poor adherence, and high rates of loss to follow in Guinea-Bissau 
increase the risk of treatment  failure7,10,14,33–35 and thus infectivity, which could reverse current encouraging 
trends in HIV prevalence. Sustained and sustainable long-term management of affected patients, combined 
with prevention, is  required10.
The Mandinga and Fula, two important West African ethnic groups, had a significantly higher prevalence of 
HIV-1 compared with other ethnic groups. A study by Kenyon et al.36 has suggested that differences in sexual 
behaviour according to ethnic group may contribute to a large variation in HIV prevalence. Previous research 
from Guinea-Bissau has suggested that female genital mutilation and polygamy among these ethnicities may 
play a  role8,37,38. Furthermore, a recent study from the HIV clinic at HNSM found Fula and Mandinga ethnicity 
to be associated with late presentation at HIV  diagnosis39. These findings underline the importance of identify-
ing vulnerable populations, understanding sociocultural motivators, and targeting interventions accordingly.
Overall, self-reported HIV treatment coverage among women accessing antenatal care increased significantly 
over the course of this study. However, only 47% of women presenting for labour had received antenatal testing 
and counselling, and only 77% of women were tested for HIV at birth, leaving a large number of women unaware 
and  untreated14. HIV-infected women not identified during pregnancy miss out on the benefits of treatment and 
prevention and remain part of a “hidden epidemic”; they are prone to late diagnosis, poor health outcomes and 
at risk of infecting their  infants40,41.
While some national interventions, such as strengthening the early provision of ART as recommended by the 
WHO, have shown  promise18, repeated political instability, and inadequate management of HIV tests and medi-
cine stocks appear to have significant negative impacts on the clinical management of HIV in the  country10,14,42. 
After a civil war in 1999, Guinea-Bissau suffered five military coups between 2002 and  201243,44, which left 
the country in a chronic state of political  instability14. This has hampered development despite national and 
international efforts and inevitably discouraged donors, as was seen in 2012 after the Global Fund, the World 
Bank, the African Development Bank and the European Union suspended HIV funding activities in Guinea-
Bissau12,21. These cuts in funding may explain the increase in HIV-infected women and their infants not receiv-
ing ART in labour in 2012 and 2013 as observed in this study, as well as the decline in national ART coverage 
from 56% in 2011 to 23% in  201421. Repeated drug stock outages were common in Guinea-Bissau9,10,42 and 
may have forced doctors and midwives to choose treatments no longer recommended by national guidelines, 
as reflected by the high proportion of women receiving sd NVP, or no treatment. In addition, a high number of 
HIV-2-infected patients received NVP, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for PMTCT. 
This is problematic because NNRTIs are ineffective against HIV-2 due to natural  resistance45. Periods of drug 
shortages and the resulting use of NNRTI-based regimes may explain the high levels of NNRTI resistance found 
in Guinea-Bissau42,46,47. Conditions in the country appear to have improved after international donors, led by the 
Global Fund, have resumed funding activities, which is reflected by a 30% increase (49.5–81.9%) in the number 
of HIV-positive mothers who received ART for PMTCT in  201421. Current estimates from UNAIDS report that 
65% of pregnant women living with HIV in Guinea-Bissau accessed ART in  201748. While these results show 
promise, overall ART coverage remains low in Guinea-Bissau48. Preliminary results from a routine analysis of 
nationwide HIV Cohort in the country show that only 14% of HIV infected individuals are aware of their HIV-
status and of these only 20% are on treatment underling the urgent need to determine the treatment retention 
and long-term outcomes of mothers and their infants during and after PMTCT 10.
This study found an increase in the number of infants not receiving PMTCT. An increase in the number of 
HIV-infected children and high rates of HIV infection (9.3%) despite PMTCT have been reported in Guinea-
Bissau, suggesting poor treatment retention and challenges to PMTCT coverage and follow-up15. While an 
increase in the number of HIV-infected children may be due to better diagnostics, the late diagnosis of children 
(median age 3.5 years) suggests a large proportion of children die before being diagnosed with  HIV15.
In line with other studies, women infected with HIV-1 and HIV-1/2 in this study had an increased risk of 
delivering LBW  babies49,50. LBW babies have an increased risk of mortality and may experience negative health 
outcomes during childhood and later in  life51. Studies have described an increasing risk of LBW with advancing 
stage of HIV  disease52, but also according to maternal ART  regimens51, emphasizing the importance of identify-
ing HIV-infected mothers early in pregnancy and insuring they receive the optimal ART regimen to improve 
health outcomes, prevent MTCT and minimize the risk of LBW.
In Guinea-Bissau, stillbirths are common. A previous study from the capital Bissau found a community 
stillbirth rate of 71/1,000 among mothers who did not attend ANC and 36/1,000 among mothers who attended 
7 or more  ANC16. While HIV infection is known to be associated with  stillbirths50, this study did not find a sig-
nificant association. Many factors affect the risk of stillbirths, including maternal age, education, marital status 
and ethnicity, in our  setting16. In addition, the stage of maternal disease, ART regimen and timing of treatment 
play a role in the risk of stillbirth and other adverse birth outcomes among HIV-infected  mothers4,53. Therefore, 
our analysis may have been limited by our inability to control sufficiently for these factors.
This study is based on data from a large sample of women presenting for labour and delivery at the country’s 
largest maternity ward and thus reflects the challenges to PMTCT services in a setting with limited resources. Our 
research has several limitations. First, the cross-sectional nature of this study means we are unable to determine 
trends in incidence and causality. Twenty-three percent of women presenting for labour during the study period 
were not counselled or tested for HIV. These women were not included in this study due to missing information 
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on HIV status presenting a potential selection bias. Data regarding condom use, number of previous partners, 
and additional high-risk behaviours were unavailable, limiting our risk factor analysis. HIV type discrimination 
was performed using SD Bioline HIV-1/2 3.0. A study from Guinea-Bissau found that SD Bioline HIV-1/2 3.0 
overestimates the number of HIV-1/2 dually infected individuals54, and high inter-observer variation was  noted55, 
which could have led to misclassification of HIV type in this study. HIV prevalence was determined based on 
women presenting at the HNSM maternity ward and may differ from women giving birth at other urban health 
centres or at home. Only half (47%) of women tested at birth reported previous testing during antenatal visits. 
There were discrepancies between self-reported antenatal test results and results at labour suggesting either 
insufficient pre and post testing counselling, lack of HIV awareness, or  stigma13, recall bias or seroconversion.
The HNSM maternity ward receives women from all parts of the capital and other regions in Guinea-Bissau 
for care and treatment of obstetric complications, yet little is known regarding the specific referral process to 
give birth. The lack of continuity of care and registration systems made it almost impossible for midwives to cor-
roborate self-reported antenatal treatment, which may have been affected by recall bias. In addition, the lack of 
confidentiality and time to perform pre- and post-test counselling at  labour13 could have limited midwives’ and 
doctors’ ability to make treatment decisions regarding the type and length of treatment based on self-reported 
antenatal treatment regimes.
Conclusion
The prevalence of HIV-1, HIV-2 and HIV-1/2 among pregnant women presenting for labour and delivery at the 
HNSM declined between 2008 and 2013. The observed increase in the proportion of women and infants not 
receiving treatment at birth is concerning. Less than half of the women in this study reported attending antenatal 
counselling and testing, and 23% were not tested in relation at birth, resulting in many mothers unaware of their 
HIV status and hence deprived of the benefits of treatment and prevention. As Guinea-Bissau continues to take 
strides towards improving PMTCT testing and ART coverage to mitigate the risk of poor health outcomes of 
HIV-infected mothers and their infants, further operational research focusing on provision of PMTCT services 
and continuity of care, retention to PMTCT services, including treatment and patient follow-up, is urgently 
needed to support future interventions and policy.
Data availability
The original data are stored at the Bandim Health Project, National Institute of Public Health in Guinea-Bissau. 
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Project (e-mail: bandim@ssi.dk). The Bandim Health Project will facilitate the request for ethical permission 
from the National Committee on Ethics in Health and provide the data on approval. We can confirm that others 
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